Previous close | 0.3720 |
Open | 0.3905 |
Bid | 0.4385 x N/A |
Ask | 0.4605 x N/A |
Day's range | 0.3905 - 0.3905 |
52-week range | 0.2435 - 0.9310 |
Volume | |
Avg. volume | 1,670 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Q1 2024 Dare Bioscience Inc Earnings Call
Explore key financial details, strategic initiatives, and forward-looking statements from Dare Bioscience's latest earnings call.
Conference Call and Webcast Today at 4:30 p.m. ETDevelopment Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United StatesSildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder successful completion of end-of-Phase 2 meeting with FDA; forthcoming additional FDA feedback; Phase 3 design, development, and